由上述研究結果向健保局申請 FDG brain PET 在相關失智症運用給付,並比照美日韓,導入amyloid tau PET的常規臨床使用。(台灣,以及美國保險給付在失智症上的差異, reference 4,5)
參考資料:
Mielke R, Pietrzyk U, Jacobs A, Fink GR, Ichimiya A, Kessler J, Herholz K, Heiss WD. HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern.Eur J Nucl Med. 1994 Oct;21(10):1052-60.
Herholz K1, Schopphoff H, Schmidt M, Mielke R, Eschner W, Scheidhauer K, Schicha H, Heiss WD, Ebmeier K. Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease.J Nucl Med. 2002 Jan;43(1):21-6.
Bentourkia M1, Bol A, Ivanoiu A, Labar D, Sibomana M, Coppens A, Michel C, Cosnard G, De Volder AG.Comparison of regional cerebral blood flow and glucose metabolism in the normal brain: effect of aging. J Neurol Sci. 2000 Dec 1;181(1-2):19-28.